Skip to main content

Table 4 Univariate analyses of the impact on overall survival in patients with CN-AML who received intensive induction chemotherapy

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variable No. of patients Overall survival
  Mediana P
Age, years    0.001 *
  60 or younger 66 32.2  
  Older than 60 22 4.5  
WBC    0.469
  50000/uL or less 49 31.433  
  Greater than 50000/uL 37 13  
BDH2    0.007 *
  Lower expression 46 53.667  
  Higher expression 40 9  
CEBPA    0.755
  Double mutation 9 31.433  
  Single mutation 16 53.667  
  No mutation 61 16.267  
NPM1    0.179
  Mutated 28 10.4  
  Wild 58 32.2  
FLT3- ITD-    <0.001*
  Mutated 17 4.767  
  Wild 70 48.633  
FLT3- TKD    0.596
  Mutated 7 13.00  
  Wild 79 18.567  
NPM1/FLT3- ITD    0.314
  NPM1+/FLT3- ITD- 15 NR  
  Others 71 15.067  
IDH1 b    0.796
  Mutated 3 22.21  
  Wild 61 27.055  
IDH2 b    0.749
  Mutated 4 21.91  
  Wild 60 27.16  
DNMT3A b    0.508
  Mutated 11 32.58  
  Wild 53 25.63  
MLL b    0.178
  Mutated 5 12.63  
  Wild 59 13.12  
BDH2 low /FLT3-ITD    <0.001*
  BDH2low/FLT3-ITDwild type 40 722.16  
  BDH2low/FLT3-ITDmutation 5 519.73  
  BDH2high/FLT3-ITDwild type 27 371.56  
  BDH2high/FLT3-ITDmutation 13 182.27  
  1. Abbreviation: NR indicates not reached.
  2. aMedian, months.
  3. bOnly 64 patients who had high quality DNA preserved for sequence received standard intensive induction chemotherapy.
  4. *Statistically significant (P < 0.05).